Cargando…

Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial †

Background: Low-molecular-weight fucoidan (LMF) is widely used as a food supplement for cancer patients. However, all of the studies are in vitro or were conducted using mice. Therefore, powerful clinical evidence for LMF use is relatively weak. This study aimed to evaluate the efficacy of LMF as a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Hsiang-Lin, Tai, Chi-Jung, Huang, Ching-Wen, Chang, Fang-Rong, Wang, Jaw-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408268/ https://www.ncbi.nlm.nih.gov/pubmed/28430159 http://dx.doi.org/10.3390/md15040122

Ejemplares similares

Low-Molecular-Weight Fucoidan as Complementary Therapy of Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer
por: Huang, Ching-Wen, et al.
Publicado: (2021)

The Auxiliary Effects of Low-Molecular-Weight Fucoidan in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy Before Surgery: A Double-Blind, Randomized, Placebo-Controlled Study
por: Tsai, Hsiang-Lin, et al.
Publicado: (2023)

A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab
por: Chang, Tsung-Kun, et al.
Publicado: (2021)

Fucoidan Supplementation Improves Exercise Performance and Exhibits Anti-Fatigue Action in Mice
por: Chen, Yi-Ming, et al.
Publicado: (2014)

Iatrogenic pseudoaneurysm after bevacizumab therapy in patients with metastatic colorectal cancer: Two case reports
por: Li, Ching-Chun, et al.
Publicado: (2018)

Combining mussel with fucoidan as a supplement for joint pain and prediabetes: Study protocol for a randomized, double-blinded, placebo-controlled trial
por: Tay, Audrey, et al.
Publicado: (2022)

Effectiveness of Fucoidan on Supplemental Therapy in Cancer Patients: A Systematic Review
por: Wu, Chih-Jung, et al.
Publicado: (2022)

Prospective double-blind randomized study on the efficacy and safety of an n-3 fatty acid enriched intravenous fat emulsion in postsurgical gastric and colorectal cancer patients
por: Ma, Cheng-Jen, et al.
Publicado: (2015)

Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting()()()
por: Ma, Cheng-Jen, et al.
Publicado: (2018)

Observational Study Comparing Efficacy and Safety between Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy for Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer
por: Yeh, Yung-Sung, et al.
Publicado: (2020)

Effects of the number of neoadjuvant therapy cycles on clinical outcomes, safety, and survival in patients with metastatic colorectal cancer undergoing metastasectomy
por: YEH, YUNG-SUNG, et al.
Publicado: (2023)

Fucoidan as a Potential Therapeutic for Major Blinding Diseases—A Hypothesis
por: Klettner, Alexa
Publicado: (2016)

Fucoidan-Supplemented Diet Potentiates Immune Checkpoint Blockage by Enhancing Antitumor Immunity
por: Yang, Juan, et al.
Publicado: (2021)

Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous UGT1A1*28 polymorphism: a single-center case series
por: Tsai, Hsiang-Lin, et al.
Publicado: (2022)

Toxicological Evaluation of Low Molecular Weight Fucoidan in Vitro and in Vivo
por: Hwang, Pai-An, et al.
Publicado: (2016)

Fucoidan Inhibition of Osteosarcoma Cells is Species and Molecular Weight Dependent
por: Gupta, Dhanak, et al.
Publicado: (2020)

Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol
por: Chen, Shang-Hung, et al.
Publicado: (2019)

Comparison of Next-Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment-Related Genomic Status in Patients with Metastatic Colorectal Cancer
por: Su, Wei-Chih, et al.
Publicado: (2022)

Evaluation of adjuvant effects of fucoidan for improving vaccine efficacy
por: Kim, Su-Yeon, et al.
Publicado: (2015)

Fucoidans in Nanomedicine
por: Chollet, Lucas, et al.
Publicado: (2016)

Effectiveness and Cost-Utility Analysis of Different Doses of Irinotecan Plus Bevacizumab in Patients With Metastatic Colorectal Cancer: A Long-Term and Prospective Cohort Study
por: Shi, Hon-Yi, et al.
Publicado: (2022)

Are Helicobacter pylori Infection and Fucoidan Consumption Associated with Fucoidan Absorption?
por: Tomori, Makoto, et al.
Publicado: (2020)

The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
por: Huang, Ching-Wen, et al.
Publicado: (2013)

Efficacy of zinc supplementation for the treatment of dysmenorrhoea: a double-blind randomised controlled trial
por: Obiagwu, Hillary I., et al.
Publicado: (2023)

Evaluation of the Efficacy of Supplementation with Planox® Lemon Verbena Extract in Improving Oxidative Stress and Muscle Damage: A Randomized Double-Blind Controlled Trial
por: Lee, Mon-Chien, et al.
Publicado: (2021)

Effects of fucoidan supplementation on inflammatory and immune response after high-intensity exercise
por: McFadden, Bridget A., et al.
Publicado: (2023)

An observational study of vascular endothelial growth factor inhibitors as second-line treatment for metastatic colorectal cancer treated with bevacizumab plus FOLFIRI beyond progression: the association with RAS mutation and tumor sidedness
por: Tsai, Hsiang-Lin, et al.
Publicado: (2019)

Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy
por: Tsai, Hsiang-Lin, et al.
Publicado: (2022)

Dietary Supplementation with Low-Molecular-Weight Fucoidan Enhances Innate and Adaptive Immune Responses and Protects against Mycoplasma pneumoniae Antigen Stimulation
por: Hwang, Pai-An, et al.
Publicado: (2019)

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer
por: Ma, Cheng-Jen, et al.
Publicado: (2017)

BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer—A Case Series Study Target Therapy of BRAF-Mutated mCRC
por: Yeh, Jen-Hao, et al.
Publicado: (2021)

UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI
por: Hsieh, Yi-Chien, et al.
Publicado: (2021)

Fucoidan-Based Nanoparticles with Inherently Therapeutic Efficacy for Cancer Treatment
por: Chiang, Chih-Sheng, et al.
Publicado: (2021)

Effects of oligo-fucoidan on the immune response, inflammatory status and pulmonary function in patients with asthma: a randomized, double-blind, placebo-controlled trial
por: Yeh, Chia-wei, et al.
Publicado: (2022)

Effectiveness of Fish Roe, Snow Fungus, and Yeast Supplementation for Cognitive Function: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Lin, Yung-Kai, et al.
Publicado: (2023)

Low Molecular Weight Fucoidan Prevents Radiation-Induced Fibrosis and Secondary Tumors in a Zebrafish Model
por: Wu, Szu-Yuan, et al.
Publicado: (2020)

Fucoidan: Structure and Bioactivity
por: Li, Bo, et al.
Publicado: (2008)

Fucoidans and Bowel Health
por: Yang, Jin-Young, et al.
Publicado: (2021)

Heparanase and Syndecan-4 Are Involved in Low Molecular Weight Fucoidan-Induced Angiogenesis
por: Haddad, Oualid, et al.
Publicado: (2015)

Preparation of Low-Molecular-Weight Fucoidan with Anticoagulant Activity by Photocatalytic Degradation Method
por: Qi, Yihui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_di6ejhsfcee1a0ju891lrf0bt9